Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
What Areas Can Be Treated
Semaglutide GLP-1 works by mimicking a natural hormone in the body that helps regulate appetite, digestion, and blood sugar
2026 DMEPOS Series #5: Immunosuppressive Drugs for Transplant - June 18, 2026 2026 DMEPOS Series #4: Continuous Glucose Monitors - May 6, 2026 Advance Beneficiary Notice of Noncoverage What You Need to Know - May 4, 2026
Abbreviations ARR: Absolute risk reduction ASCVD: Atherosclerotic cardiovascular disease CANVAS: Canagliflozin Cardiovascular Assessment Study CKD: Chronic kidney disease CVD: Cardiovascular disease CVOT: Cardiovascular outcomes trial DKA: Diabetic ketoacidosis DPP-4: Dipeptidyl peptidase-4 DPP-4i: Dipeptidyl peptidase-4 inhibitor DSMES: Diabetes self-management education and support EMPA-REG OUTCOME: Empagliflozin, Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients ESRD: End-stage renal disease EXSCEL: Exenatide Study of Cardiovascular Event Lowering GLP-1: Glucagon-like peptide-1 GLP-1 RA: Glucagon-like peptide-1 receptor agonist HF: Heart failure LEADER: Liraglutide Effect and Action in Diabetes: Evaluation of of Cardiovascular Outcomes Results MACE: Major adverse cardiac events MI: Myocardial infarction MNT: Medical nutrition therapy RCT: Randomised clinical trial SGLT2: Sodiumglucose cotransporter-2 SGLT2i: Sodiumglucose cotransporter-2 inhibitor SMBG: Self-monitoring of blood glucose SU: Sulfonylurea SUSTAIN 6: Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes T2DM: Type 2 diabetes mellitus TZD: Thiazolidinedione UKPDS: UK Prospective Diabetes Study References Rodriguez-Gutierrez R, Gionfriddo MR, Ospina NS et al (2016) Shared decision making in endocrinology: present and future directions
Niacinamide Reduces dullness and improves elasticity
